Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast

Cancer Epidemiology Biomarkers and Prevention

Volumn 10, Issue 3, 2001, Pages 249-259

  Hoque, Ashraful ^a   Lippman, Scott M ^a   Boiko, Iouri V ^a   Atkinson, Edward N ^a   Sneige, Nour ^a   Sahin, Aysegul ^a   Weber, Diane M ^a   Risin, Seymon ^a   Lagios, Michael D ^b   Schwarting, Roland ^c   Colburn, William J ^d   Dhingra, Kapil ^e   Follen, Michele ^a   Kelloff, Gary J ^f   Boone, Charles W ^f   Hittelman, Walter N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Breast Cancer Consultation Service St Mary Hospital and Medical Center Pathology   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d Providence Tarzana Medical Center   (United States)

^e HOFFMANN LA ROCHE INC   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; FRACTAL ANALYSIS; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MORPHOMETRICS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CASE-CONTROL STUDIES; COHORT STUDIES; CONFIDENCE INTERVALS; DNA, NEOPLASM; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INCIDENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEAR MATRIX; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROBABILITY; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 0035730925     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999
2. Ductal carcinoma in situ of the breast
3. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low-grade ductal carcinoma in situ of the breast treated only by biopsy
4. Ductal carcinoma in situ treated with lumpectomy and irradiation: Histopathological analysis of 49 specimens with emphasis on risk factors and long term results
5. Ductal carcinoma in situ. The success of breast conservation therapy: A shared experience of two single institution non-randomized prospective studies
6. Predictors of local recurrence after treatment of ductal carcinoma in situ. A meta-analysis
7. Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy
8. Long-term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery. The effect of age
9. Ductal carcinoma in situ: Long-term results of breast-conserving therapy
10. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised Phase III trial 10853
11. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17
12. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
13. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-I Study
14. Relationship between the size and margin status of ductal carcinoma in situ of the breast and residual disease
15. The influence of margin width on local control of ductal carcinoma in situ of the breast
16. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ)
17. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence
18. Ductal carcinoma in situ: Pathology and treatment
19. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ
20. Duct carcinoma in situ: 227 Cases without microinvasion
21. Subclinical ductal carcinoma in situ of the breast: Treatment by local excision and surveillance alone
22. Nottingham experience
23. Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ
24. A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): Correlation with grade of associated invasive cancer
25. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma
26. Interlaboratory variations in the grading of breast carcinoma
27. Importance of nuclear morphology in breast cancer prognosis
28. Nuclear morphometry as an intermediate endpoint biomarker in chemoprevention of cervical carcinoma using α-difluoromethylornithine
29. Computed cell cycle and DNA histogram analyses in image cytometry in breast cancer
30. Reproducibility of mean nuclear volume and correlation with mean nuclear area in breast cancer: An investigation of various sampling schemes
31. Nuclear shape and axillary metastases in breast cancer: Analytic morphometry of aspiration smears
32. Image cytophotometric DNA analysis of atypical hyperplasias and intraductal carcinomas of the breast
33. Prognostic significance (relapse, non-relapse) of nuclear shape parameters in lymph node negative breast cancer
34. The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis
35. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: A critical analysis
36. Prognostic factors in patients with stage I, estrogen receptor-negative carcinoma of the breast: A clinicopathologic study
37. Identification of a low-risk group stage 1 breast cancer patients by cytometrically assessed DNA and nuclear texture parameters
38. Nuclear texture measurements in image cytometry
39. An algorithm for predicting non-organ confined prostate cancer using the results obtained from sextant core biopsies and prostate specific antigen level
40. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy
41. Data representation and reduction for chromatin texture in nuclei from premalignant prostatic, esophageal, and colonic lesions
42. Ability to predict biochemical progression using Gleason score and computer-generated quantitative nuclear grade derived from cancer cell nuclei
43. Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials
44. Malignancy-associated in the breast. Changes in chromatin distribution in epithelial cells in normal-appearing tissue adjacent to carcinoma
45. Risk of recurrence after ductal carcinoma in situ of the breast
46. Predicting the likelihood of residual disease in women treated for ductal carcinoma in situ
47. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci
48. Chromosomal alterations in ductal carcinoma in situ and their in situ recurrence
49. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast
50. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells
51. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis
52. Tissue structure, nuclear organization, and gene expression in normal and malignant breast